Combination use of medicines from two classes of renin–angiotensin system blocking agents: Risk of hyperkalemia, hypotension, and impaired renal function

Therapeutic Advances in Drug Safety

Volumn 6, Issue 4, 2015, Pages 166-176

  Esteras, Raquel ^a   Perez Gomez, Maria Vanessa ^a   Rodriguez Osorio, Laura ^a   Ortiz, Alberto ^a   Fernandez Fernandez, Beatriz ^b  

^a Section of Nephrology   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

aldosterone; angiotensin; diabetic nephropathy; drug safety; heart failure; patiromer; potassium; Renin Angiotensin Aldosterone System (RAAS) blockade; Renin Angiotensin System (RAS) blockers; zirconium cyclosilicate

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FINERENONE; LISINOPRIL; LOSARTAN; MINERALOCORTICOID ANTAGONIST; PATIROMER; PLACEBO; RAMIPRIL; SODIUM ZIRCONIUM CYCLOSILICATE; SPIRONOLACTONE; TELMISARTAN; VALSARTAN;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ALBUMINURIA; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; CONSTIPATION; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FAINTNESS; FETUS DISEASE; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MICROALBUMINURIA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 84938403458     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098615589905     Document Type: Review

References (52)

1. Ando K. Ohtsu H. Uchida S. Kaname S. Arakawa Y. Fujita T. (2014) Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2: 944–953.
2. Atlas S. (2007) The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 13: 9–20.
3. Ben S. Badreddine A. Fathallah N. Slim R. Hmouda H. (2014) Drug-induced hyperkalemia. Drug Saf 37: 677–692.
4. Benito-Martin A. Ucero A. Zubiri I. Posada-Ayala M. Fernandez-Fernandez B. Cannata-Ortiz P. (2013) Osteoprotegerin in exosome-like vesicles from human cultured tubular cells and urine. PLoS One 8: e72387.
5. Brem A. Morris D. Gong R. (2011) Aldosterone-induced fibrosis in the kidney: questions and controversies. Am J Kidney Dis 58: 471–479.
6. Brilla C. Weber K. (1992) Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 26: 671–677.
7. Catapano F. Chiodini P. De N. Minutolo R. Zamboli P. Gallo C. (2008) Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 52: 475–485.
8. Cheng J. Zhang X. Tian J. Li Q. Chen J. (2012) Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis. Int J Clin Pract 66: 917–923.
9. de Zeeuw D. (2013) The end of dual therapy with renin-angiotensin-aldosterone system blockade? N Engl J Med 369: 1960–1962.
10. Delyani J. (2000) Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 57: 1408–1411.
11. Ellison D. Ingelfinger J. (2014) A quest – halting the progression of autosomal dominant polycystic kidney disease. N Engl J Med 371: 2329–2331.
12. Epstein M. (2014) Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney disease. Lancet Diabetes Endocrinol 2: 925–927.
13. Fernandez F. Elewa U. Sanchez-Nino M. Rojas-Rivera J. Martin-Cleary C. Egido J. (2012) 2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials. Minerva Med 103: 219–234.
14. Fernandez J. Luno J. Barrio V. de Vinuesa S. Praga M. Goicoechea M. (2013) Effect of dual blockade of the renin–angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis 61: 211–218.
15. Fernandez-Fernandez B. Ortiz A. Gomez-Guerrero C. Egido J. (2014) Therapeutic approaches to diabetic nephropathy – beyond the RAS. Nat Rev Nephrol 10: 325–346.
16. Fernandez-Juarez G. Barrio V. de Vinuesa S. Goicoechea M. Praga M. Luno J. (2006) Dual blockade of the renin–angiotensin system in the progression of renal disease: the need for more clinical trials. J Am Soc Nephrol 17: S250–S254.
17. Fried L. Emanuele N. Zhang J. Brophy M. Conner T. Duckworth W. (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369: 1892–1903.
18. Gentile G. Remuzzi G. Ruggenenti P. (2015) Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny. Nephron. 129(1): 39–41. doi: 10.1159/000368331.
19. Harel Z. Harel S. Shah P. Wald R. Perl J. Bell C. (2013) Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med 126: 264.e9–24.
20. Hunsicker L. Adler S. Caggiula A. England B. Greene T. Kusek J. (1997) Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51: 1908–1919.
21. Ingelfinger J. (2015) A new era for the treatment of hyperkalemia? N Engl J Med 372: 275–277.
22. Jennings D. Kalus J. Coleman C. Manierski C. Yee J. (2007) Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 24: 486–493.
23. Juurlink D. Mamdani M. Lee D. Kopp A. Austin P. Laupacis A. (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543–551.
24. K/DOQI Workgroup (2005) K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45: S1–S153.
25. Kolkhof P. Delbeck M. Kretschmer A. Steinke W. Hartmann E. Barfacker L. (2014) Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 64: 69–78.
26. Kunz R. Friedrich C. Wolbers M. Mann J. (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148: 30–48.
27. MacKinnon M. Shurraw S. Akbari A. Knoll G. Jaffey J. Clark H. (2006) Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 48: 8–20.
28. Makani H. Bangalore S. Desouza K. Shah A. Messerli F. (2013a) Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 346: f360.
29. Makani H. Bangalore S. Messerli F. (2013b) Optimal renin–angiotensin system blockade – wishful thinking? Nat Rev Cardiol 10: 486.
30. McMurray J. Young J. Dunlap M. Granger C. Hainer J. Michelson E. (2006) Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J 151: 985–991.
31. Nussberger J. Bohlender J. (2013) Pharmacotherapy: optimal blockade of the renin-angiotensin-aldosterone system. Nat Rev Cardiol 10: 183–184.
32. Packham D. Rasmussen H. Lavin P. El-Shahawy M. Roger S. Block G. (2014) Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015 Jan 15; 372(3): 222–31.
33. Parving H. H. Brenner B. M. McMurray J. J. de Zeeuw D. Haffner SM. Solomon SD. (2012) ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 6; 367(23): 2204–2213.
34. Pitt B. Kober L. Ponikowski P. Gheorghiade M. Filippatos G. Krum H. (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34: 2453–2463.
35. Pitt B. Zannad F. Remme W. Cody R. Castaigne A. Perez A. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709–717.
36. Posada-Ayala M. Zubiri I. Martin-Lorenzo M. Sanz-Maroto A. Molero D. Gonzalez-Calero L. (2014) Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. Kidney Int 85: 103–111.
37. Preston R. Afshartous D. Garg D. Medrano S. Alonso A. Rodriguez R. (2009) Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease. Hypertension 53: 754–760.
38. Rossing K. Schjoedt K. Smidt U. Boomsma F. Parving H. (2005) Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28: 2106–2112.
39. Ruggenenti P. Cravedi P. Remuzzi G. (2012) Mechanisms and treatment of CKD. J Am Soc Nephrol 23: 1917–1928.
40. Ruggenenti P. Perticucci E. Cravedi P. Gambara V. Costantini M. Sharma S. (2008) Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 19: 1213–1224.
41. Schmieder R. Klingbeil A. Fleischmann E. Veelken R. Delles C. (2005) Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 16: 3038–3045.
42. Schrier R. Abebe K. Perrone R. Torres V. Braun W. Steinman T. (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371: 2255–2266.
43. Siwy J. Schanstra J. Argiles A. Bakker S. Beige J. Boucek P. (2014) Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrol Dial Transplant 29: 1563–1570.
44. Susantitaphong P. Sewaralthahab K. Balk E. Eiam-ong S. Madias N. Jaber B. (2013) Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis. Am J Hypertens 26: 424–441.
45. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293–302.
46. Torres V. Abebe K. Chapman A. Schrier R. Braun W. Steinman T. (2014) Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med 371: 2267–2276.
47. Van Buren P. Adams-Huet B. Nguyen M. Molina C. Toto R. (2014) Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clin J Am Soc Nephrol 9: 295–301.
48. Weir M. Bakris G. Bushinsky D. Mayo M. Garza D. Stasiv Y. (2014) Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15; 372(3): 211–21.
49. Weir M. Rolfe M. (2010) Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 5: 531–548.
50. Yusuf S. Teo K. Pogue J. Dyal L. Copland I. Schumacher H. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559.
51. Zubiri I. Posada-Ayala M. Sanz-Maroto A. Calvo E. Martin-Lorenzo M. Gonzalez-Calero L. (2013) Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis. J Proteomics 96C: 92–102.
52. Zurbig P. Jerums G. Hovind P. MacIsaac R. Mischak H. Nielsen S. (2012) Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 61: 3304–3313.